Active cancer treatment is the clearest case in the entire HDHP versus PPO analysis where the PPO wins. Year-one billed costs typically run $150,000 to $500,000 for solid tumours, far higher for advanced disease requiring immunotherapy or stem cell transplant. Both an HDHP and a PPO will hit their out-of-pocket maximums during a treatment year, so the question becomes which plan has the lower OOP max and the more predictable copay schedule between now and that ceiling.
This page covers the cost arithmetic, the never-switch-mid-treatment rule, the continuity-of-care argument that often dominates pure cost math, and the specific protections cancer patients have under the ACA, No Surprises Act, and 2022 Inflation Reduction Act.
The billed cost trajectory depends heavily on cancer type and stage. The figures below are illustrative composites based on the NCCN and National Cancer Institute treatment guidelines and aggregated insurance claims data from MEPS and Peterson-KFF Health System Tracker analyses.
| Treatment phase | Typical duration | Billed cost range | What it includes |
|---|---|---|---|
| Diagnosis and staging | 1-2 months | $15,000-$40,000 billed | Imaging, biopsies, oncology consults, pathology |
| Surgery | 1 episode + 2-6 weeks recovery | $30,000-$120,000 billed | Tumour resection, possible reconstruction, inpatient stay |
| Adjuvant chemotherapy | 4-6 months | $60,000-$200,000 billed | Multiple infusion cycles, supportive care drugs, frequent labs |
| Radiation therapy | 5-7 weeks | $25,000-$80,000 billed | Daily treatments, planning imaging, recovery support |
| Targeted / immunotherapy | 6-12+ months | $100,000-$300,000+ billed | Monoclonal antibodies, infusion every 2-4 weeks |
| Surveillance follow-up | 5+ years | $5,000-$15,000/year billed | Periodic imaging, oncology visits, labs |
On a 2026 IRS-minimum HDHP, the self-only OOP max is $8,500. On a typical employer PPO, the OOP max is $4,000 to $6,000. That ceiling difference of $2,500 to $4,500 is the floor of the annual savings. Add the timing-of-spend factor: HDHP patients hit the OOP max in the first 2 to 6 weeks of treatment (the diagnosis-and-staging phase plus first surgery), creating a single massive cash-flow event. PPO patients pay copays per visit spread across the treatment year, with each round of chemotherapy adding $100 to $500 in copays rather than full coinsurance.
For a multi-year treatment regimen, the difference compounds. A 5-year hormonal therapy course (common for hormone-receptor-positive breast cancer) involves 5 years of $500 to $1,200 per month tamoxifen or aromatase inhibitor costs, plus quarterly oncology visits, plus annual surveillance imaging. Each year on an HDHP, you pay the $1,700+ deductible plus coinsurance on prescriptions until OOP max. On a PPO, the same care costs $30 to $50 per office visit plus tiered prescription copays of $10 to $80 per fill. Annual savings on multi-year regimens: $3,000 to $6,000 per year.
Cancer diagnosis is not a qualifying life event under federal rules, you cannot switch mid-year. You can only change plans at the annual open enrollment or with a separate QLE (marriage, divorce, birth, job change, loss of other coverage). This creates a strategic question if diagnosis happens mid-year and you are on an HDHP: do nothing now and switch at next open enrollment if treatment continues, or stay on HDHP through both years.
The math usually favours switching at the next open enrollment if any active treatment continues into the new plan year. The PPO advantage of $3,000 to $6,000 per year on multi-year treatment regimens is large enough to justify the premium overhead. The exception: if your HDHP network is materially better for your specific oncology team (e.g. your preferred academic cancer centre is in HDHP network but not PPO network), continuity of care is worth more than the dollar savings. Confirm network status before switching.
The trap to avoid: switching from one PPO to another PPO mid-treatment because the new one looks cheaper. Different PPOs often have different oncology networks, formularies, and prior authorisation rules. Mid-treatment authorisation re-approval can delay chemotherapy by weeks. The American Society of Clinical Oncology has documented prior authorisation delays as a meaningful source of treatment interruption per ASCO position statements. Unless premium savings are massive, stay on the plan that has your treatment plan already approved.
Cancer treatment is relational. Your medical oncologist, surgical oncologist, radiation oncologist, oncology nurse navigator, and infusion centre staff are your treatment team. Established relationships, transferred records, ongoing genomic test results, and continuity in side-effect management all matter clinically. Forcing a plan switch that disrupts the team can cost more in delayed treatment, missed adjustments, and emotional load than the dollar savings recover.
Before switching plans in active treatment, verify in writing that every member of your treatment team is in-network on the new plan. Confirm the specific infusion centre is in-network, not just "the cancer center". Confirm the laboratory used for molecular testing is in-network. Confirm radiation therapy is delivered at an in-network facility. Get this in writing from the new insurer's pre-treatment estimate, not just from the network directory, which is often outdated.
The HDHP wins occasionally in cancer scenarios when the household income is very high (which makes the HSA tax shield worth more), the employer HSA seed is very large (some large employers contribute $3,000+ to seed HDHPs for self-funded employees with new diagnoses, though this is rare), and the treatment is short (a single resection with no chemo or radiation, typical of some early-stage thyroid or basal-cell skin cancers).
For most cancer treatment scenarios, however, the PPO wins consistently. The HSA tax shield, even at high incomes, rarely compensates for the $3,000 to $6,000 per year of additional out-of-pocket exposure on multi-year regimens.
The HSA balance can be spent on cancer treatment costs regardless of which plan you are currently on. You do not need to remain on an HDHP to spend the HSA, only to contribute to it. If you have built a meaningful HSA balance over years of HDHP enrollment, treatment year is the time to spend it down tax-free on copays, deductibles, prescriptions, transportation to treatment, lodging during distant treatment (up to $50/night per patient per IRS rules), and any qualifying out-of-pocket cost.
The receipt-pile trick from earlier compounding still works. If you have accumulated $30,000 of unreimbursed past medical receipts and now face a $5,500 PPO OOP max for the treatment year, you can pull $5,500 from the HSA tax-free, which counts against your accumulated reimbursable receipts. The HSA effectively becomes a tax-free reserve for the highest-cost medical year of your life.
You cannot switch mid-year without a qualifying life event, cancer diagnosis is not a QLE. For the remainder of the calendar year, your HDHP will hit its OOP max quickly (often within the first round of imaging and biopsies), and the rest of your in-network treatment is covered at 100 percent. At the next open enrollment, switch to the PPO if treatment will continue into the new plan year. The PPO advantage in year 2 of treatment can be $4,000 to $8,000 in patient cost.
Switch to PPO for as long as active treatment continues. Adjuvant chemotherapy (post-surgery preventive chemo) typically lasts 4 to 6 months. Hormonal therapy for breast cancer can last 5 to 10 years. Immunotherapy for various cancers can be ongoing. Each treatment year, you will hit the OOP max on an HDHP. PPO copays and lower OOP max ceilings cap your annual exposure thousands lower.
Yes. The ACA prohibits annual and lifetime dollar caps, requires coverage of essential health benefits including cancer screening, treatment, and many follow-up services. The 2022 Inflation Reduction Act capped Medicare Part D out-of-pocket at $2,000/year starting 2025, which helps cancer patients on expensive oral chemotherapy. Some state laws provide additional protections, particularly for clinical trial participation coverage. Read your plan's SBC carefully, but most ACA-compliant plans now cover the major treatment categories.
The federal No Surprises Act (effective January 2022) protects you from surprise out-of-network billing for emergency services and for out-of-network providers at in-network facilities (anaesthesiologist, radiologist, pathologist). For planned cancer treatment, confirm in advance that your surgeon, oncologist, radiation oncologist, pathology lab, and infusion centre are all in-network. The NSA does not protect against fully out-of-network choices, only surprises within in-network facilities.
Yes. All qualified medical expenses under IRS Publication 502 are HSA-eligible, including chemotherapy, radiation, surgery, hospital stays, prescription drugs, transportation to treatment (at the IRS medical mileage rate, 21 cents/mile for 2025), and lodging up to $50/night per patient when treatment requires travel. The HSA can fund treatment costs tax-free regardless of which plan you are currently on (you do not need to be on an HDHP to spend HSA balance, only to contribute to it).
Not medical, insurance, or financial advice. Cost estimates are composite ranges from NCCN treatment guidelines, NCI cost data, MEPS aggregated claims data, and Peterson-KFF Health System Tracker analyses. Individual treatment plans, geographic location, facility type, and disease stage create wide variance. Work with your oncology team's financial navigator and a Patient Advocate Foundation case manager for plan-specific guidance during active treatment.